“This technology results in membranes that solve critical issues in the production of biopharmaceuticals as well as having the potential to significantly improve membrane functional attributes in industrial and laboratory settings.” – Dr. Li.

The biomanufacturing and pharmaceutical membrane filtration market is large, estimated at just over $5B USD for 2019 and expected to double by 2025. The technology behind Filtravate allows membranes to be built from the ground up using the smallest building block to create controlled pore sizes, even pore distribution, and allows for tuning of the membrane surface properties to meet the exact needs of the end user. “This allows us to meet major unmet market needs in bioprocessing” continued Dr. Li, as current membrane products lack the combination of high flow rates, low membrane fouling (blocking), and precise separation capabilities at the nanoscale over long use periods.